NCT07158346View on ClinicalTrials.gov

Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

L03RD1

1 tablet of L03RD1

DRUG

L03RD2

2 tablets of L03RD2

DRUG

CT-L03

1 tablet of CT-L03

Trial Locations (1)

08756

RECRUITING

H plus Yangji Hostpital, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT07158346 - Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers | Biotech Hunter | Biotech Hunter